WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 6 fonti

FDA Approves First PCSK9 Inhibitor in Pill Form

With enlicitide, large LDL cholesterol reductions possible without a needle

Raccontata dahealio.combiopharmadive.commedpagetoday.comnbcnews.comperfil.combenzinga.com

Confronto fonti

6 prospettive sulla stessa storia
AI · summaries
medpagetoday.comStai leggendo16 h fa

FDA Approves First PCSK9 Inhibitor in Pill Form

With enlicitide, large LDL cholesterol reductions possible without a needle

originale
healio.com

Timeline cronologica

  1. giovedì 16 luglio 2026·healio.com

    FDA approves Lipfendra, the first oral PCSK9 inhibitor, to lower LDL

    Merck and the FDA announced the approval of enlicitide 20 mg as an add-on to diet and exercise to lower LDL in adults with hypercholesterolemia and those with heterozygous…

  2. giovedì 16 luglio 2026·biopharmadive.com

    Merck wins first approval of a PCSK9 cholesterol pill

    The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former commissioner Marty Makary.

1 g fa

FDA approves Lipfendra, the first oral PCSK9 inhibitor, to lower LDL

Merck and the FDA announced the approval of enlicitide 20 mg as an add-on to diet and exercise to lower LDL in adults with hypercholesterolemia and those with heterozygous familial hypercholesterolemia.Enlicitide…

Leggi questa versione → originale
perfil.com14 h fa

La FDA aprobó la primera pastilla que promete mejorar significativamente el tratamiento del colesterol alto

El organismo regulador de medicinas de los EE. UU. autorizó el uso recetado de “enlicitide”. Este medicamento reduce en hasta un 60% el colesterol LDL y ofrece una alternativa a otros tratamientos. Está destinado a…

Leggi questa versione → originale
biopharmadive.com1 g fa

Merck wins first approval of a PCSK9 cholesterol pill

The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former commissioner Marty Makary.

Leggi questa versione → originale
nbcnews.com15 h fa

FDA approves new kind of cholesterol pill

Merck’s pill, called Lipfendra, is a PCSK9 inhibitor, which works in a different way than a statin to lower cholesterol.

Leggi questa versione → originale
benzinga.com9 h fa

FDA Approval Adds New Cholesterol Treatment Option in Merck Portfolio - Merck & Co (NYSE:MRK)

Merck's Lipfendra wins FDA approval as the first oral PCSK9 inhibitor for adults with high LDL cholesterol after positive Phase 3 results.

Leggi questa versione → originale
  • giovedì 16 luglio 2026·medpagetoday.com

    FDA Approves First PCSK9 Inhibitor in Pill Form

    With enlicitide, large LDL cholesterol reductions possible without a needle

  • giovedì 16 luglio 2026·nbcnews.com

    FDA approves new kind of cholesterol pill

    Merck’s pill, called Lipfendra, is a PCSK9 inhibitor, which works in a different way than a statin to lower cholesterol.

  • giovedì 16 luglio 2026·perfil.com

    La FDA aprobó la primera pastilla que promete mejorar significativamente el tratamiento del colesterol alto

    El organismo regulador de medicinas de los EE. UU. autorizó el uso recetado de “enlicitide”. Este medicamento reduce en hasta un 60% el colesterol LDL y ofrece una alternativa a…

  • giovedì 16 luglio 2026·benzinga.com

    FDA Approval Adds New Cholesterol Treatment Option in Merck Portfolio - Merck & Co (NYSE:MRK)

    Merck's Lipfendra wins FDA approval as the first oral PCSK9 inhibitor for adults with high LDL cholesterol after positive Phase 3 results.